Skip to main content
Publish date:

Generex Biotech Rises on New Coverage

Shares move higher on a buy rating from Torc Investments and Research.

Generex Biotechnology's


stock got a lift Wednesday on new analyst coverage.

Torc Investments and Research initiated coverage of the Florida-based company with a buy rating and a 12-month price target of $3-$3.50.

TheStreet Recommends

Shares moved higher, closing Wednesday up 16 cents, or roughly 10%, at $1.76.